new post
StocksRunner logo
mail
search
 
menu
 
Cardiff Oncology Inc
$1.60
+1.27%
 
  Set Alerts  
  
  Overview  
  
  Comments  
  
  Insights  
  
     Risks     
  
  Rating  
  
     Chart     
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Headlines  
 

CRDF Stock Analysis & IQ Rating | Cardiff Oncology Inc

 
 

CRDF

 

Cardiff Oncology Inc

$1.60

 
+$0.02 | +1.27%
 
Set Alerts
 
  Overview  
  
  Comments  
  
  Insights  
  
     Risks     
  
  Rating  
  
     Chart     
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Headlines  
 
 
52W High
$4.99
 
 
MKT CAP
$111.14M
 
52W Low
$1.48
 
 
VOL
$579.79K
 
P/E Ratio
N/A
 
 
AVG VOL
$1.51M
 
RSI
32.94
 
 
TREND
Downtrend
 
 
 

CRDF Stock IQ

 
lock  Login to see Cardiff Oncology Inc (CRDF) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
 
 

CRDF Target Price

 
 
 
 

CRDF Price Performance

 
 

$2.88   (-44.44%)

$2.04   (-21.57%)

$2.07   (-22.71%)

$3.82   (-58.12%)

 
 
1year
6month
3month
1month
 

CRDF Analysts Opinion

 

Overall standing based on market and analyst consensus. menu Hover over the category for more information

 
 
 

Earnings

×
 

Earnings

 
 
 

Rating

×
 

Rating

 
 

Momentum

×
 

Momentum

 

CRDF Momentum Analysis

 Price value has negative momentum

 

Activity

×
 

Activity

 
 

Future

×
 

Future

 
 
 

CRDF Analysts Opinion

CRDF Analysts opinion is negative and it remained unchanged from the past 3 months

 

CRDF Street Sentiment

 

Analysts perspectives on the stock desirability, trend direction and growth potential

 
 
80%
Buy
Opinion
Trend
Score
Potential
Score
 
Consensus Rating
 
NA
0%
NA
 

CRDF Street Sentiment 

CRDF Street Sentiment is extremely bullish and have negative views on the near-term outlook

 

CRDF Risk Level

 
 

CRDF has Extreme risk level

 
 

Risks Indicators

 Beta greater than 1.0

 Price under $5

 High volatilty

 
 
CRDF Risk Level
Extreme
LOW
HIGH
 

CRDF Performance Sentiment

 
Sentiments overview associated with events and the stock performance
 
 
80%
20%
Positive
Negative
4 out of 5
events present
1 out of 5
events present
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
 

Key Price Levels

 

Average key support and resistance price levels

 
 
Support
Price
 
$1.58
 
Resistance
Price
 
$1.48
 
 
Current Price Range
 
$3.18
 
 
Show methods +
 
 
CRDF Latest Analysis +
 
 
FAQ About CRDF Stock Insights
 

What is CRDF current stock price?

What are CRDF stock strengths?

What is CRDF Risk Level?

What is CRDF market cap and volume?

What is CRDF current Stock IQ?

Should I buy CRDF stock right now?

Is CRDF a Strong Buy right now?

What does a 'Strong Buy' rating mean for CRDF?

What does a 'Strong Sell' rating mean for CRDF?

What factors influence CRDF's Stock IQ?

 
 
StocksRunner

Explore our CRDF Stock insights

  • In-Depth Market Analysis and Trends
  • Expert Insights on Market Dynamics
  • Tailored CRDF Stock Strategies
  • Effective Risk Management
 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our CRDF Daily Alerts

Join over 5,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

 
Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

 
Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

 
Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

 
About StocksRunner

Log In

Sign Up

Plans & Pricing

Contact Us

Terms of use

Privacy Policy

 
 
 
 

CRDF

 

Cardiff Oncology Inc

 
Set Alerts
 
 

Current Price

 

$1.60

 
+$0.02 | +1.27%
 
 
52W High
$4.99
 
 
MKT CAP
$111.14M
 
52W Low
$1.48
 
 
VOL
$579.79K
 
P/E Ratio
N/A
 
 
AVG VOL
$1.51M
 
RSI
32.94
 
 
TREND
Downtrend
 
 
 
  Overview  
  
  Comments  
  
  Insights  
  
   Risks   
  
  Rating  
  
  Chart  
  
  Analysts  
  
  Street  
  
  Sentiment  
 
 
 
 
user
 
 
 
 

CRDF Price Performance

 
 

$2.88   (-44.44%)

$2.04   (-21.57%)

$2.07   (-22.71%)

$3.82   (-58.12%)

 
 
1year
6month
3month
1month
 

CRDF Analysts Opinion

 

Overall standing per market and analyst expectations. menu Hover over the category for more information

 
 
 

Earnings

×
 

Earnings

 
 
 

Rating

×
 

Rating

 
 

Momentum

×
 

Momentum

 

CRDF Momentum Sentiment

 Price value has negative momentum

 

Activity

×
 

Activity

 
 

Future

×
 

Future

 
 
 

CRDF Analysts Opinion

CRDF Analysts opinion is negative and it remained unchanged from the past 3 months

 

CRDF Street Sentiment

 

Analysts perspectives on the stock desirability, trend direction and growth potential

 
 
80%
Buy
Opinion
Trend
Score
Potential
Score
 
Consensus Rating
 
NA
0%
NA
 

CRDF Street Sentiment 

CRDF Street Sentiment is extremely bullish and have negative views on the near-term outlook

 

CRDF Risk Level

 
 

CRDF has Extreme risk level

 
 

Risks Indicators

 

 Beta greater than 1.0

 Price under $5

 High volatilty

 
 
CRDF Risk Level
Extreme
LOW
HIGH
 
CRDF Performance Sentiment
 
Sentiments overview associated with events and the stock performance.
 
 
80%
20%
Positive
Negative
4 out of 5
events present
1 out of 5
events present
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 

Key Price Levels

 

Average key support and resistance price levels

 
 
Support
Price
 
$1.58
 
Resistance
Price
 
$1.48
 
 
Current Price Range
 
$3.18
 
 
Show methods +
 
 
 
 
 
 

CRDF Stock IQ

 
 
 
lock  Login to unlock Cardiff Oncology Inc (CRDF) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
 
 
 

Target Price

 
 
 
 
 
 
 

Stock Insights

 
 
 

Not Enough Information

 
 
 

CRDF Latest Analysis

 
 
 

CRDF: New CEO Presents Phase II Readout. By On January 27th 2026 Cardiff Oncology Inc. (NASDAQ:CRDF) announced that its CEO Dr. Mark Erlander and CFO James Levine stepped down from their roles. The new chief executive officer is Dr. Mani Mohindru who has been on Cardiffs board since 2021. the lead finance role was assumed by Brigitte Lindsay who was appointed as Chief Accounting Officer. Along with the appointment of new executives the company select data from its Phase II trial in onvansertib

 

Tue Feb 3, 2026

$1.68 | -1.75%
 
Activity

Cardiff Oncology Stock Plunges After Sudden Leadership Change Narrowed Trial Focus. ) on Tuesday closed around 32% lower after the management update and trial update.To maintain financial continuity “.The leadership transition reflects the Company’.s focus on execution and clinical advancement as its programs mature”. the company on Tuesday.Concurrently Cardiff Oncology announced an update from CRDF-004 a randomized dose-finding Phase 2 trial evaluating onvansertib in combination

 

Wed Jan 28, 2026

$1.62 | -19.00%
 
Activity
Momentum
 
 
 
 
 
StocksRunner

Discover CRDF Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of CRDF. We're here to help you make informed investment decisions today.

 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our CRDF Daily Alerts

Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

 
Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

CRDF Stock trends

CRDF Stock performance

CRDF Stock analysis

CRDF investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

 
 

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
StocksRunner logo
 

CRDF Alerts

Real-time signals powered by data
×

Price-Based

Triggers when the stock breaks through a known resistance level
 
Triggers when the stock drops below a key support level
 
Notifies if the stock moves up/down by a set percentage (e.g. ±5%)
 
Alerts when the stock hits a new high or low
 
Signals proximity to long-term highs or lows (e.g. within 5%)
 

Technical Indicator (Pro Plan)

Volume spikes 2x–3x above average. Indicates strong buying/selling pressure
 
Tracks large intraday swings, signaling potential opportunities or risk
 
Signals potential trend reversals or continuations
 
Long-term bullish/bearish trend signals from MA crossovers
 
RSI above 70 or below 30 to identify possible reversals
 
Signals momentum shifts
 

Fundamental Indicator (Master Plan)

Upcoming or just-released earnings reports
 
Alerts after results compared to expectations
 
Changes in rating or target price
 
New or changed dividends
 
Large trades by company insiders
 
M&A, lawsuits, product launches, etc
 
High volume/open interest in call/put contracts
 
Surge in mentions or sentiment shifts
 
 
Cancel
 
×
 
0/666
joker
 
Post
 
✕
 
StocksRunner logo
 

Don't Be a Sheep, Be a StocksRunner

 

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

 
StocksRunner thumbnail
 
 

Sign up for free and

continue analysing CRDF

 
Signup to Stocksrunner
 

Already a Member? Click here to Login

 

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

 
✕
 
StocksRunner logo
 

Don't Be a Sheep, Be a StocksRunner

 

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

 
StocksRunner thumbnail
 
 

Sign up for free and

continue analysing CRDF

 
Signup to Stocksrunner
 

Already a Member? Click here to Login

 

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.